Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin effects on postprandial lipemia, inflammation, and vascular function in insulin-treated men with type 2 diabetes
NL-OMON46285Phase 4Active, not recruiting
- Sponsor
- Franciscus Gasthuis & Vlietland
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in type 2 diabetes mellitus (T2DM) comparing dapagliflozin with placebo (2 arms). Primary endpoint: Postprandial leukocyte activation. Started Sep 2017; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON46285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46285.